Several studies report that BACE1 inhibitors hold great potential as a potential strategy in decreasing Aβ brain concentrations, thus preventing the progression of AD (Citron, 2002; De Strooper et al., 2010). This evidence concerns the gene BACE1 and Alzheimer disease.